Search
IGN101
go.drugbank.com/drugs/DB06500ExperimentalIGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.
Muraglitazar
go.drugbank.com/drugs/DB06510Investigationalin LDL-C levels. … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingAMGN-0007
go.drugbank.com/drugs/DB06511ExperimentalRecombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Robalzotan
go.drugbank.com/drugs/DB06538ExperimentalSynonyms: (R)-3-(Dicyclobutylamino)-8-fluoro-5-chromancarboxamideCategories: Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor AntagonistsR107474
go.drugbank.com/drugs/DB06553ExperimentalSynonyms: 3-(2-(3,4-Dihydrobenzofuro(3,2-c)pyridin-2(1H)-yl)ethyl)-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one, 3-[2-(3,4-dihydro-1H-[1]benzofuro[3,2-c]pyridin-2-yl)ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-oneCategories: Heterocyclic Compounds, 1-Ring